Long-term portosystemic shunt patency as a determinant of outcome in Budd-Chiari syndrome

被引:35
作者
Bachet, Jean-Baptiste
Condat, Bertrand
Hagege, Herve
Plessier, Aurelie
Consigny, Yann
Belghiti, Jacques
Valla, Dominique
机构
[1] Hop Beaujon, Serv Hepatol, F-92118 Clichy, France
[2] Ctr Hosp Intercommunal, Serv Hepatogastroenterol, Creteil, France
[3] Hop Beaujon, Serv Chirurg Viscerale, Clichy, France
关键词
transjugular intrahepatic portosystemic shunting; Budd-Chiari syndrome; surgical portosystemic shunt; hepatocellular carcinoma; refractory ascites; prosthetic grafts;
D O I
10.1016/j.jhep.2006.08.016
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Portosystemic shunting, whether surgical or transjugular intrahepatic, has been a cornerstone of therapy for Budd-Chiari syndrome. However, the long-term impact of shunt dysfunction remains unknown. We have assessed this long-term impact in patients with surgical shunting. Methods: Thirty-nine consecutive patients operated on between 1978 and 2000 were analyzed using time-dependent multivariate Cox model. Results: Median follow-up was 110 months. Prosthetic shunts and high preshunt portal venous pressure were predictors of subsequent shunt dysfunction. Among 19 patients with persistently patent shunt, as compared to 20 patients with shunt dysfunction, 1 versus 18 developed refractory ascites; 1 versus 7 had variceal bleeding; 7 versus 2 had encephalopathy; 3 versus 11 (55%) died or underwent liver transplantation; and 0 versus 10 died from end-stage liver disease. Shunt dysfunction was associated with a shorter survival (p = 0.001). Out of 20 patients with shunt dysfunction, seven had successful revision of the shunt. None of these seven patients had refractory ascites after revision or died from end-stage liver disease. Conclusions: In patients with Budd-Chiari syndrome treated with portosystemic shunting, shunt dysfunction has a major impact on morbidity and mortality. (c) 2006 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:60 / 68
页数:9
相关论文
共 30 条
  • [1] AHN SS, 1987, SURGERY, V101, P165
  • [2] Patients with cirrhosis and bare-stent TIPS may have increased risk of hepatocellular carcinoma
    Bañares, R
    Núñez, O
    Escudero, M
    Fernández, C
    Vaquero, J
    Beceiro, I
    Echenagusía, A
    Clemente, G
    Santos, L
    [J]. HEPATOLOGY, 2005, 41 (03) : 566 - 571
  • [3] BLAKEMORE AH, 1948, SURG CLIN N AM, V28, P279
  • [4] Arterial and portal circulation and parenchymal changes in Budd-Chiari syndrome: A study in 17 explanted livers
    Cazals-Hatem, D
    Vilgrain, V
    Genin, P
    Denninger, ML
    Durand, FO
    Belghiti, J
    Valla, D
    Degott, C
    [J]. HEPATOLOGY, 2003, 37 (03) : 510 - 519
  • [6] COX DR, 1972, J R STAT SOC B, V34, P187
  • [7] THE CHANGING SCENE OF HEPATIC VEIN-THROMBOSIS - RECOGNITION OF ASYMPTOMATIC CASES
    HADENGUE, A
    POLIQUIN, M
    VILGRAIN, V
    BELGHITI, J
    DEGOTT, C
    ERLINGER, S
    BENHAMOU, JP
    [J]. GASTROENTEROLOGY, 1994, 106 (04) : 1042 - 1047
  • [8] Havlioglu N, 2003, AM J GASTROENTEROL, V98, P201
  • [9] PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome
    Hernández-Guerra, M
    Turnes, J
    Rubinstein, P
    Olliff, S
    Elias, E
    Bosch, J
    García-Pagán, JC
    [J]. HEPATOLOGY, 2004, 40 (05) : 1197 - 1202
  • [10] Budd-Chiari syndrome: a review by an expert panel
    Janssen, HLA
    Garcia-Pagan, JC
    Elias, E
    Mentha, G
    Hadengue, A
    Valla, DC
    [J]. JOURNAL OF HEPATOLOGY, 2003, 38 (03) : 364 - 371